A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States

Medical Decision Making

Volumn 28, Issue 1, 2008, Pages 44-55

  Barton, Pelham M ^a   Moayyedi, Paul ^b   Talley, Nicholas J ^c,d   Vakil, Nimish B ^e   Delaney, Brendan C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Computer simulation; Cost benefit analysis; Dyspepsia

Indexed keywords

ANTACID AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL PRACTICE; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DYSPEPSIA; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; PARAMETER; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; RELAPSE; UNITED STATES;

ADULT; COST-BENEFIT ANALYSIS; DYSPEPSIA; FINANCING, PERSONAL; HELICOBACTER PYLORI; HUMANS; META-ANALYSIS AS TOPIC; MIDDLE AGED; MODELS, STATISTICAL; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SAMPLING STUDIES; UNITED STATES;

EID: 38349165398     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X07309644     Document Type: Article

References (58)

1. Ramsey S., Willke R., Briggs A., et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005 ; 8: 521 - 33.
2. Sonnenberg FA, Beck JR Markov models in medical decision making: a practical guide. Med Decis Making. 1993 ; 13: 322 - 38.
3. Barton P., Bryan S., Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004 ; 9: 110 - 8.
4. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005 ; 129: 1753 - 5.
5. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology. 2005 ; 129: 1756 - 80.
6. Ford AC, Qume M., Moayyedi P., et al. Helicobacter pylori test and treat or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology. 2005 ; 128: 1838 - 44.
7. Silverstein MD, Petterson T., Talley NJ Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology. 1996 ; 110: 72 - 83.
8. Briggs AH, Sculpher MJ, Logan RP, Aldous J., Ramsay ME, Baron JH Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ. 1996 ; 312: 1321 - 5.
9. Laheij RJ, Severens JL, Jansen JB, van de Lisdonk EH, Verbeek AL Management in general practice of patients with persistent dyspepsia: a decision analysis. J Clin Gastroenterol. 1997 ; 25: 563 - 7.
10. Delaney BC, Moayyedi P., Deeks J., et al. The management of dyspepsia: a systematic review. Health Technol Assess. 2000 ; 4: 1 - 187.
11. Phillips C., Moore A. Implementing evidence-based medical interventions: the cost-effectiveness of Helicobacter pylori diagnosis and eradication. Br J Med Econ. 1996 ; 10: 47 - 57.
12. Ebell MH, Warbasse L., Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract. 1997 ; 44: 545 - 55.
13. Ofman JJ, Etchason J., Fullerton S., Kahn KL, Soil AH Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med. 1997 ; 126: 280 - 91.
14. Sonnenberg A., Delco F., Inadomi JM When to eradicate Helicobacter pylori? A decision analytic approach. Gastroenterol Int. 1997 ; 10: 1 - 7.
15. McIntyre AM, Macgregor S., Malek M., Dunbar JA, Hamley JG, Cromarty JA New patients presenting to their GP with dyspepsia: does Helicobacter pylori eradication minimise the cost of managing these patients? Int J Clin Pract. 1997 ; 51: 276 - 81.
16. Spiegel BM, Vakil NB, Ofman JJ Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology. 2002 ; 122: 1270 - 85.
17. Philips Z., Ginnelly L., Sculpher M., et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004 ; 8: 1 - 158.
18. Talley NJ, Colin-Jones D., Koch KL, Koch M., Nyren O., Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int. 1991 ; 4: 145 - 60.
19. The Danish Dyspepsia Group. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol. 2001 ; 96: 1417 - 21.
20. Chiba N., Thompson ABR, Barkun AN, et al. The Rome II definition of dyspepsia does not exclude patients with GERD in primary care. Gastroenterology. 2003 ; 124 (suppl 2). A1572.
21. Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med. 1999 ; 72: 93 - 100.
22. www.drugstore.com. Accessed 1 April 2004.
23. Macran S., Weatherly H., Kind P. Measuring population health: a comparison of three generic health status measures. Med Care. 2003 ; 41: 218 - 31.
24. Dyspepsia: Managing Adults in Primary Care. London: National Institute of Clinical Excellence; 2004.
25. Roberts AP, Childs S., Rubin G., de Wit NJ Tests for Helicobacter pylori infection: a critical appraisal from primary care. Fam Pract. 2000 ; 17 (suppl 2). S12 - 20.
26. Moayyedi P., Deeks J., Talley NJ, Delaney BC, Forman D. An update of the Cochrane Systematic Review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003 ; 98: 2621 - 6.
27. Moayyedi P., Delaney B., Vakil N., Forman D., Talley NJ The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004 ; 127: 1329 - 37.
28. Moayyedi P., Deeks J., Talley NJ, Delaney B., Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003 ; 98: 2621 - 6.
29. Stinnett AA, Paltiel AD Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making. 1997 ; 17: 483 - 9.
30. Briggs AH Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol. 2004 ; 16: 551 - 61.
31. O'Brien BJ, Briggs AH Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002 ; 11: 455 - 68.
32. Delaney BC, Deeks J., Wilson S., Moayyedi P., Forman D. Initial management strategies for dyspepsia (full Cochrane Review). In: The Cochrane Library. Issue 2. Oxford, UK: Update Software ; 2003.
33. Stevens R., Baxter G. Benefit of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care. Gastroenterology. 2001 ; 120 (suppl 1). A50.
34. Ciba N., Veldhuyzen van Zanten SJO, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Helicobacter pylori positive (CADET-H.pylori) randomised controlled trial. BMJ. 2002 ; 324: 1012 - 7.
35. Jarbol D., Kragstrup J., Havelund T., Schafallitzky de Muckadell O. Efficacy of three strategies based on empirical antisecretory therapy and Helicobacter pylori status for the management of dyspepsia in general practice: a randomized controlled trial. Dig Dis Wk. 2004 ; A530.
36. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther. 1995 ; 9 (suppl 2). 3 - 12.
37. Cullen DJE, Collins J., Christiansen KJ, Epis J., Warren JR, Cullen KJ Long term risk of peptic ulcer disease in people with Helicobacter pylori infection: a community based study. Gastroenterology. 1993 ; 104: A60.
38. Sipponen P., Varis K., Fraki O., Korri UM, Seppala K., Siurala M. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis: a clinical follow-up study of 454 outpatients. Scand J Gastroenterol. 1990 ; 25: 966 - 73.
39. Kuipers EJ, Thijs JC, Festen HP The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995 ; 9 (suppl 2). 59 - 69.
40. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992 ; 102: 1259 - 68.
41. Dent J., Brun J., Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut. 1999 ; 44: S1 - 16.
42. Jones RH, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut. 1990 ; 31: 401 - 5.
43. Delaney BC, Wilson S., Roalfe A., et al. A randomised controlled trial of Helicobacter pylori test and endoscopy for dyspepsia in primary care. BMJ. 2001 ; 322: 898 - 901.
44. Cullen DJE, Collins J., Christiansen KJ, Epis J., Warren JR, Cullen KJ Long term risk of peptic ulcer disease in people with Helicobacter pylori infection: a community based study. Gastroenterology. 1993 ; 104: A60.
45. Agreus L. Natural history of dyspepsia. Gut. 2002 ; 50 (suppl IV). iv2 - 9.
46. Chiba N., de Gara CJ, Wilkinson JM, Hunt RH Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997 ; 112: 1798 - 1810.
47. Ford A., Delaney B., Forman D., Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients (full Cochrane review). In: The Cochrane Library. Issue 4. Chichester, UK: John Wiley ; 2003.
48. van Pinxteren B., Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane review). In: The Cochrane Library. Issue 2. Oxford, UK: Update Software ; 2003.
49. Cloud ML, Enas N., Humphries TJ, Bassion S. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci. 1998 ; 43: 993 - 1000.
50. Earnest DL, Dorsch E., Jones J., Jennings DE, Greski-Rose PA A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol. 1998 ; 93: 238 - 43.
51. Hetzel DJ, Dent J., Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988 ; 95: 903 - 12.
52. Sontag S., Hirschowitz BI, Holt S., et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US multicentre study. Gastroenterology. 1992 ; 102: 109 - 18.
53. Silvis SE, Farahmand M., Johnson JA, Ansel HJ, Ho SB A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointest Endosc. 1996 ; 43: 216 - 21.
54. Edwards SJ, Lind T., Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001 ; 15: 1729 - 36.
55. Sharma VK, Leontiadis GI, Howden CW Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001 ; 15: 227 - 31.
56. Delaney BC, Moayyedi P. Eradicating H. pylori does not cause gastro-oesophageal reflux disease. BMJ. 2004 ; 328: 1388 - 9.
57. Moayyedi P., Soo S., Deeks J., et al. Systematic review: antacids, H2 receptor antagonists, prokinetics, bismuth and sucralfate therapy for non ulcer dyspepsia. Aliment Pharmacol Ther. 2003 ; 17: 1215 - 27.
58. Groeneveld PW, Lieu TA, Fendrick AM, et al. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol. 2001 ; 96: 338 - 47.